Tri­fec­ta of clin­i­cal stage biotechs un­veil IPO plans, brav­ing Wall Street's coro­n­avirus pan­ic

Coro­n­avirus fears pre­cip­i­tat­ed a rout on glob­al stock prices on Mon­day, but three clin­i­cal-stage biotechs are sol­dier­ing on with plans to make pub­lic de­buts. The biggest is Zen­tal­is Phar­ma­ceu­ti­cals — which is gun­ning for a $100 mil­lion IPO, three months af­ter an $85 mil­lion round of fi­nanc­ing.

Found­ed in late 2014, the on­col­o­gy com­pa­ny emerged out of stealth in late 2019 with the Se­ries C round. So far the com­pa­ny has raised about $162 mil­lion in gross pro­ceeds.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.